Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Date:11/10/2010

onship with Perrigo.

For the nine months ended September 30, 2010, the Company's marketing and selling expenses decreased 8%, or $15,000, to $185,000 compared to $200,000 for the comparable period in 2009. This decrease was primarily due to a decrease in personnel- related expenses, advertising and tradeshow expenses, offset by an increase in sales brokerage related expenses associated with the planned distribution of the nutritional products.  

General and administrative expenses decreased 42%, or $1.4 million, to $1.9 million for the nine months ended September 30, 2010, compared to $3.3 million for the same period in 2009, primarily due to a reduction in personnel related costs through headcount reductions and reductions in executive compensation.

Research and development expenses decreased 61%, or $1.3 million, to $853,000 for the nine months ended September 30, 2010, compared to $2.2 million for the same period in 2009, primarily due to reductions in personnel and other expenses reflecting the deferral of development activities for certain product candidates.

The net loss for the nine months ended September 30, 2010, decreased 52%, or $2.7 million, to $2.4 million, compared with a net loss of $5.1 million for the same period in 2009. This decrease was primarily due to lower overall operating expenses.

About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http:
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. SCOLR Pharma, Inc. Licenses Dietary Supplements
5. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
8. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
9. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
10. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
11. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... development of DG041 as an,effective anti-platelet that ... June 25, 2007 /PRNewswire-FirstCall/ --,deCODE genetics today ... company's Phase II developmental compound for the,prevention ... Phase IIa and,clinical pharmacology studies presented today ...
... Improving Glycemic Control and,Reducing Diabetic Cardiovascular Complications, ... VeroScience, LLC,in conjunction with its commercialization partner ... its Phase IIIb clinical trial,supporting the overall ... formulation of bromocriptine mesylate) in subjects,with type ...
Cached Medicine Technology:Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific ... compliance issues that may have raised the risk of ... just posted an article on the research. Click ... found airborne asbestos levels well above OSHA safety guidelines ... 2011. , “Asbestos compliance sampling data associated with the ...
(Date:5/24/2015)... Aliso Viejo, CA (PRWEB) May 24, 2015 ... for use in Final Cut Pro X. Utilize ProPin to ... locations in a given scene. , ProPin allows users ... are completely customizable in FCPX. With on-screen controls, video editors ... Studios allows users to pin and mark with absolute ease. , ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... Washington, D.C. (PRWEB) May 23, 2015 ... demonstration of powers of a youngster's yogic power learned ... by Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, ... of more than 50 high profile professionals attending the ... D.C. by reading fluently -- blindfolded. , In ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... , FRIDAY, Feb. 4 (HealthDay News) -- Middle-aged breast cancer ... normally uncommon in women younger than 70, a new study ... that this may be because early menopause caused by breast ... weaken the bones by the time women reach middle age. ...
... be a feminine trait, but for women with peripheral artery ... point to the smaller calf muscles of women as a ... problems walking and climbing stairs sooner and faster than men ... the February 2011 issue of the Journal of the ...
... can prevent 90 percent of genital warts in men when ... the vaccine, according to a new multi-center study led by ... international clinical trial, which also found a nearly 66 percent ... prior exposure to these strains, provides the first reported results ...
... Reporter , THURSDAY, Feb. 3 (HealthDay News) -- While the ... new analysis backs the possibility that cold-like viruses might trigger ... studies, and concluded there is a strong association between enteroviruses ... with diabetes were 10 times more likely to have had ...
... people in employment, men and women who are unemployed suffer ... Why the un-employed should have health problems more often is ... current issue of Deutsches rzteblatt International (Dtsch Arztebl ... findings of the GEDA study. , The GEDA study (Gesundheit ...
... systematic review carried out by a team at the ... studies and concluded that there are benefits to mental ... environment. Their findings are published in the leading research ... February 2011. The research team, supported by the ...
Cached Medicine News:Health News:Breast Cancer Treatment May Lead to Hip Fracture 2Health News:Peripheral artery disease harder on women 2Health News:HPV vaccine works for boys: Study shows first clear benefits 2Health News:Cold Viruses Appear Linked to Type 1 Diabetes 2Health News:Cold Viruses Appear Linked to Type 1 Diabetes 3Health News:Review confirms benefits of outdoor exercise 2Health News:Review confirms benefits of outdoor exercise 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: